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Histamine is used as an adjunct to interleukin-2 (IL-2) in
tumor immunotherapy due to its protective effect on NK
and T cell inhibition by monocyte-derived reactive oxygen
metabolites in vitro. Results from a first randomized phase
III trial showed an increase in survival in stage IV
melanoma patients with liver involvement (Agarwala SS,
J Clin Oncol 2002, 20). Here we have analyzed the effect of
histamine on T cell cytokine production in patients
treated with IL-2 without or with histamine within a sec-
ond randomized multicenter phase III trial. A significant
increase (mean 2.2-fold) in frequencies of CD3+ T cells
producing IFN-γ (T1 cells) in response to mitogen stimu-
lation was detected in patients treated with histamine plus
IL-2 (n = 7 patients) while IL-2 alone (n = 10 patients) had
no effect on the frequency of IFNγ-producing CD3+ T
cells. In contrast, frequencies of CD3+ T cells producing
IL-13 (T2 cells) significantly increased in patients receiv-
ing IL-2 (mean 2.7-fold) and this effect was not modu-
lated by histamine (mean increase 2.9-fold). These effects
were observed for both CD3+CD8+ as well as CD3+CD4+
T cells. In vitro experiments using separated T cells and
monocytes from healthy subjects show that while hista-
mine does not induce IFN-γ production in T cells it pro-
tects T cells from monocyte-induced down-regulation of
IFN-γ. Melanoma-specific T cell responses were analyzed
in the 9 HLA-A2+ patients (IL2 + histamine, n = 4; IL-2, n
= 5) against HLA-A2+ melanoma cell lines using intra-cel-
lular cytokine staining. Induction or augmentation of
melanoma-reactive IFN-γ and IL-13-producing T cells
could be shown in 2 HLA-A2-positive melanoma patients
treated with histamine and IL-2, but in none of the
patients in the IL-2 arm. Both patients had received previ-
ous vaccination with HLA-A*0201 binding tyrosinase
peptide and also tyrosinase-specific T cell responses were
detected after IL-2 plus histamine treatment. In summary,
treatment with histamine in combination with IL-2
increases T1 responses and stimulates melanoma-specific
T cells.
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